KalVista Pharmaceuticals, Inc. Forecast, price target & analysts
KalVista Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
KalVista Pharmaceuticals, Inc. Classifications & Recommendation:
KalVista Pharmaceuticals, Inc. Price Target
| Target Price | $30.60 |
| Price | $15.46 |
| Potential |
97.93%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target KalVista Pharmaceuticals, Inc. 2027 .
The average KalVista Pharmaceuticals, Inc. target price is $30.60.
This is
97.93%
register free of charge
$40.95
164.88%
register free of charge
$22.22
43.73%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend KalVista Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the KalVista Pharmaceuticals, Inc. stock has an average upside potential 2027 of
97.93%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Apr '25 |
2026 Estimates |
|---|
11 Analysts have issued a sales forecast KalVista Pharmaceuticals, Inc. 2026 . The average KalVista Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an KalVista Pharmaceuticals, Inc. EBITDA forecast 2026. The average KalVista Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2027 |
$-160m
20.17%
Unlock
|
|
|---|---|---|
EBITDA Margin
| 2027 |
-86.64%
73.75%
Unlock
|
|
|---|---|---|
11 KalVista Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average KalVista Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Apr '25 |
2026 Estimates |
|
|---|---|---|
| P/E | negative | |
| EV/Sales | 11.88 |
11 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast for earnings per share. The average KalVista Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
KalVista Pharmaceuticals, Inc....
Current KalVista Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Dec 04 2025 |
| Citizens |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 11 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Jul 08 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Dec 04 2025 |
|
Locked
Citizens:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 11 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Jul 08 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 08 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
